We are live on ! Find out more
ATRS

Antares Pharma, Inc.
ATRS

Delisted

ATRS was delisted on the 23rd of May, 2022.

Back to rankings

1 hedge funds and large institutions have $12K invested in Antares Pharma, Inc. in 2022 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 172 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 177 → 1 (-176)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $375M → $12K (-$375M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 172

Holders
1
Holders Change
-176
Holders Change %
-99.44%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
172
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
-$49M
2
RCMNY
Rubric Capital Management (New York)
New York
-$44.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
-$35.4M
4
SIG
Sargent Investment Group
Maryland
-$15M
5
State Street
State Street
Massachusetts
-$14.1M
Name Holding Trade Value Shares
Change 		Change in
Stake
DWA
151
Douglass Winthrop Advisors
New York
– -$41K -10,000 Closed
KPW
152
Kore Private Wealth
New York
– -$41K -10,000 Closed
OAM
153
Oak Asset Management
California
– -$41K -10,000 Closed
SRC
154
Shufro Rose & Co
New York
– -$41K -10,000 Closed
TCM
155
Traynor Capital Management
Pennsylvania
– -$41K -10,000 Closed
CG
156
Cutler Group
California
– -$31K -7,786 Closed
UBS Group
157
UBS Group
Switzerland
– -$23K -5,700 Closed
FDCDDQ
158
Federation des caisses Desjardins du Quebec
Quebec, Canada
– -$20.5K -5,000 Closed
RTC
159
Riverview Trust Company
Washington
– -$17K -4,192 Closed
SPIA
160
Steward Partners Investment Advisory
New York
– -$16K -4,000 Closed
PHK
161
Point72 Hong Kong
Hong Kong
– -$16K -3,961 Closed
TRCT
162
Tower Research Capital (TRC)
New York
– -$13K -3,285 Closed
CAPTRUST Financial Advisors
163
CAPTRUST Financial Advisors
North Carolina
– -$13K -3,160 Closed
Federated Hermes
164
Federated Hermes
Pennsylvania
– -$10K -2,473 Closed
US Bancorp
165
US Bancorp
Minnesota
– -$8K -1,990 Closed
EWA
166
EverSource Wealth Advisors
Alabama
– -$6K -1,352 Closed
UB
167
UMB Bank
Missouri
– -$4K -1,000 Closed
C
168
Covestor
United Kingdom
– -$3K -644 Closed
JMF
169
Johnson Midwest Financial
Iowa
– -$2K -500 Closed
T
170
TCWP
Ohio
– -$1K -336 Closed
ED
171
Exane Derivatives
France
– -$426 -104 Closed
3 4 5 6
7

ATRS Hedge Fund Activity: Q2 2022 in Review

1 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Antares Pharma, Inc. (ATRS) for Q2 2022, worth a combined $12K — down 100% from $375M a quarter earlier.

Sellers outnumbered buyers: 172 funds closed out of ATRS and 0 opened new positions — a net loss of 172 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was BlackRock, exiting entirely with an estimated $49M sold.

  • 1 institutional investor held Antares Pharma, Inc. (ATRS) as of Q2 2022, down from 177 in Q1 2022.
  • Funds reported $12K of Antares Pharma, Inc. stock for Q2 2022, down 100% quarter-over-quarter.
  • 0 funds opened new Antares Pharma, Inc. positions in Q2 2022 and 172 closed out, a net change of -172 holders.
  • The largest Antares Pharma, Inc. seller in Q2 2022 was BlackRock, an estimated $49M sold.

Based on aggregated 13F filings for Q2 2022.